Literature DB >> 11960360

Postremission therapy in older adults with acute myeloid leukemia: an opportunity for new drug development.

C A Schiffer1.   

Abstract

Entities:  

Mesh：

Year:  2002        PMID： 11960360     DOI： 10.1038/sj.leu.2402487

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission.

Authors:  Sherif S Farag; Kati Maharry; Mei-Jie Zhang; Waleska S Pérez; Stephen L George; Krzysztof Mrózek; John DiPersio; Donald W Bunjes; Guido Marcucci; Maria R Baer; Mitchell Cairo; Edward Copelan; Corey S Cutler; Luis Isola; Hillard M Lazarus; Mark R Litzow; David I Marks; Olle Ringdén; David A Rizzieri; Robert Soiffer; Richard A Larson; Martin S Tallman; Clara D Bloomfield; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2011-06-21       Impact factor: 5.742

2.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

Authors:  Sherif S Farag; Kellie J Archer; Krzysztof Mrózek; Amy S Ruppert; Andrew J Carroll; James W Vardiman; Mark J Pettenati; Maria R Baer; Mazin B Qumsiyeh; Prasad R Koduru; Yi Ning; Robert J Mayer; Richard M Stone; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

3.  Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.

Authors:  Sook-Kyoung Heo; Eui-Kyu Noh; Dong-Joon Yoon; Jae-Cheol Jo; Jae-Hoo Park; Hawk Kim
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.